返回 
加入收藏
直接口服抗凝药用于肿瘤相关静脉血栓预防的临床综合评价体系研究
x
请在关注微信后，向客服人员索取文件
| 篇名： | 直接口服抗凝药用于肿瘤相关静脉血栓预防的临床综合评价体系研究 |
| TITLE： | Clinical comprehensive evaluation framework for direct oral anticoagulants in the prevention of cancer-associated venous thromboembolism |
| 摘要： | 目的 构建直接口服抗凝药（DOACs）用于肿瘤相关静脉血栓栓塞（CAVTE）预防的临床综合评价体系，为CAVTE的合理防治、抗凝药物宏观管理策略的制定及调整提供支持和参考。方法通过文献检索，收集整理评价指标，初步建立指标池；以指标重要性评分均值≥3.5及变异系数（CV）＜0.25为筛选指标，通过两轮德尔菲法开展评价指标遴选，采用层次分析法（AHP）最终明确指标权重。结果两轮专家咨询的权威程度（C）r分别为0.877、0.943，CV分别为0.24、0.18，Kendall协调系数分别为0.331、0.535（P＜0.05）。经两轮专家咨询论证，最终将6个一级指标及46个二级指标纳入评价体系。一级指标及权重排序依次为“有效性”（38.86%）“、安全性”（38.86%）“、经济性”（10.67%）“、可及性”（5.51%）“、适宜性”（3.48%）“、创新性”（2.64%）。二级指标组合权重范围为0.02%～20.25%，排前5位的依次为“颅内大出血发生率”（20.25%）“、全因死亡风险的降低”（15.29%）“、肺栓塞发生率的降低”（8.82%）“、深静脉血栓发生率的降低”（7.25%）和“药物使用禁忌证”（4.74%）。结论本研究建立了权威、科学、可靠的DOACs用于CAVTE预防的药品临床综合评价体系。 |
| ABSTRACT： | OBJECTIVE To establish a clinical comprehensive evaluation framework for direct oral anticoagulants （DOACs） in the prevention of cancer-associated venous thromboembolism （CAVTE）， providing a methodological reference for the rational prevention and treatment of CAVTE as well as for the formulation and adjustment of macro-management strategies for anticoagulant drugs. METHODS Through literature retrieval， evaluation indicators were collected and organized to establish a preliminary indicator pool. The selection of evaluation indicators was carried out through two rounds of Delphi surveys using average score of indicator importance≥3.5 and a coefficient of variation （CV） ＜0.25 as the screening criteria. Analytic hierarchy process （AHP） was employed to finalize the indicator weights. RESULTS The authority levels （C）r of the two rounds of expert consultations were 0.877 and 0.943， with CV of 0.24 and 0.18， respectively. The Kendall concordance coefficients were 0.331 and 0.535 （P＜0.05）. After expert validation， six primary indicators and forty-six secondary indicators were finalized for inclusion in the evaluation framework. The primary indicators and their weightings， ranked in descending order， were as follows：“ effectiveness” （38.86%）， “safety” （38.86%），“ cost-effectiveness” （10.67%），“ accessibility” （5.51%），“ suitability” （3.48%）， and “innovation” （2.64%）. The secondary indicators exhibited a weight range from 0.02% to 20.25%， with the top five secondary indicators being：“ incidence of intracranial hemorrhage” （20.25%）， “reduction in all-cause mortality” （15.29%）， “decrease in the incidence of pulmonary embolism” （8.82%）， “reduction in the incidence of deep vein thrombosis” （7.25%）， and “drug contraindications” （4.74%）. CONCLUSIONS This study has established an authoritative， scientific， and reliable comprehensive clinical evaluation framework for the use of DOACs in the prevention of CAVTE. |
| 期刊： | 2025年第36卷第11期 |
| 作者： | 吴玥；沈秉正；张帆；曾俊芬；刘妍灼；刘刚；周本宏 |
| AUTHORS： | WU Yue，SHEN Bingzheng，ZHANG Fan，ZENG Junfen，LIU Yanzhuo，LIU Gang，ZHOU Benhong |
| 关键字： | 直接口服抗凝药；肿瘤相关静脉血栓；临床综合评价；德尔菲专家咨询；层次分析法 |
| KEYWORDS： | direct oral anticoagulants； cancer-associated |
| 阅读数： | 13 次 |
| 本月下载数： | 0 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
